Navigation Links
Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results

le.com">invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
3. Choosing Lab Quality Management Software
4. Optimizing Quality Control Data Management
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
11. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
Post Your Comments:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 1The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 3Two Powerful Companies One Powerhouse in Protection 55790 1Two Powerful Companies One Powerhouse in Protection 55790 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 1Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 3